{"id":476062,"date":"2021-04-14T08:03:38","date_gmt":"2021-04-14T12:03:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/"},"modified":"2021-04-14T08:03:38","modified_gmt":"2021-04-14T12:03:38","slug":"hookipa-pharma-to-present-at-kempen-life-science-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/","title":{"rendered":"HOOKIPA Pharma to Present at Kempen Life Science Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK and VIENNA, Austria, April  14, 2021  (GLOBE NEWSWIRE) &#8212; HOOKIPA Pharma Inc. (NASDAQ: HOOK, \u2018HOOKIPA\u2019), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA\u2019s management team will participate and host 1:1 meetings at the virtual Kempen Life Science Conference, taking place April 21, 2021.<\/p>\n<p>Additional information will be available within the Investors &amp; Media section of HOOKIPA\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y-2_D8aPa-JZ_pAE38gGsipCu0rVA5fVVxeHWajg-cJW6tL_zpJDeDn2bIxUhpGb3_68c-wlg-beb_kAfghHDP6TRJmS3oBHq7zc_6gkOGB71fmMp7ueS-hnI6Fkjw7g\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.hookipapharma.com\/events<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About HOOKIPA<\/strong><br \/>\n        <br \/>HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body\u2019s immune system.<\/p>\n<p align=\"justify\">HOOKIPA\u2019s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+\u00a0T cells and pathogen-neutralizing antibodies. HOOKIPA\u2019s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+\u00a0T cell response levels previously not achieved by other immuno-therapy approaches.<\/p>\n<p align=\"justify\">HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1\/2 clinical trial.<\/p>\n<p align=\"justify\">HOOKIPA\u2019s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.<\/p>\n<p align=\"justify\">Find out more about HOOKIPA online at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r6EwanRoqkb_0OiEo7fsuG99RV5P4MAskdEn2zRBDU1yR_fSCWCQwEuKwumbDnyvyOXFReV-QZ_cyctUtcph2Bav331_85R8fjrk0za3ob0=\" rel=\"nofollow noopener\" target=\"_blank\">www.hookipapharma.com<\/a>.<\/p>\n<p>For further information, please contact:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:30%;width:30%;min-width:30%\">\n            <strong>Media<\/strong>\n          <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%\">\u00a0<\/td>\n<td style=\"max-width:65%;width:65%;min-width:65%\">\n            <strong>Investors<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Nina Waibel<\/td>\n<td>\u00a0<\/td>\n<td>Matt Beck<\/td>\n<\/tr>\n<tr>\n<td>Senior Director &#8211; Communications<\/td>\n<td>\u00a0<\/td>\n<td>Executive Director &#8211; Investor Relations<\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:nina.waibel@hookipapharma.com\" rel=\"nofollow noopener\" target=\"_blank\">nina.waibel@hookipapharma.com<\/a>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\n            <a href=\"mailto:matthew.beck@hookipapharma.com\" rel=\"nofollow noopener\" target=\"_blank\">matthew.beck@hookipapharma.com<\/a>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjgxOSM0MTIwNTY3IzIxNTY5MjI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/23e05807-033c-4966-b228-b72ced590036\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK and VIENNA, Austria, April 14, 2021 (GLOBE NEWSWIRE) &#8212; HOOKIPA Pharma Inc. (NASDAQ: HOOK, \u2018HOOKIPA\u2019), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA\u2019s management team will participate and host 1:1 meetings at the virtual Kempen Life Science Conference, taking place April 21, 2021. Additional information will be available within the Investors &amp; Media section of HOOKIPA\u2019s website at https:\/\/ir.hookipapharma.com\/events. About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body\u2019s immune system. HOOKIPA\u2019s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+\u00a0T cells and pathogen-neutralizing antibodies. HOOKIPA\u2019s viral vectors target &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;HOOKIPA Pharma to Present at Kempen Life Science Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-476062","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HOOKIPA Pharma to Present at Kempen Life Science Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HOOKIPA Pharma to Present at Kempen Life Science Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK and VIENNA, Austria, April 14, 2021 (GLOBE NEWSWIRE) &#8212; HOOKIPA Pharma Inc. (NASDAQ: HOOK, \u2018HOOKIPA\u2019), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA\u2019s management team will participate and host 1:1 meetings at the virtual Kempen Life Science Conference, taking place April 21, 2021. Additional information will be available within the Investors &amp; Media section of HOOKIPA\u2019s website at https:\/\/ir.hookipapharma.com\/events. About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body\u2019s immune system. HOOKIPA\u2019s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+\u00a0T cells and pathogen-neutralizing antibodies. HOOKIPA\u2019s viral vectors target &hellip; Continue reading &quot;HOOKIPA Pharma to Present at Kempen Life Science Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-14T12:03:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjgxOSM0MTIwNTY3IzIxNTY5MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HOOKIPA Pharma to Present at Kempen Life Science Conference\",\"datePublished\":\"2021-04-14T12:03:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/\"},\"wordCount\":316,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjgxOSM0MTIwNTY3IzIxNTY5MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/\",\"name\":\"HOOKIPA Pharma to Present at Kempen Life Science Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjgxOSM0MTIwNTY3IzIxNTY5MjI=\",\"datePublished\":\"2021-04-14T12:03:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjgxOSM0MTIwNTY3IzIxNTY5MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjgxOSM0MTIwNTY3IzIxNTY5MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-present-at-kempen-life-science-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HOOKIPA Pharma to Present at Kempen Life Science Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HOOKIPA Pharma to Present at Kempen Life Science Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/","og_locale":"en_US","og_type":"article","og_title":"HOOKIPA Pharma to Present at Kempen Life Science Conference - Market Newsdesk","og_description":"NEW YORK and VIENNA, Austria, April 14, 2021 (GLOBE NEWSWIRE) &#8212; HOOKIPA Pharma Inc. (NASDAQ: HOOK, \u2018HOOKIPA\u2019), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA\u2019s management team will participate and host 1:1 meetings at the virtual Kempen Life Science Conference, taking place April 21, 2021. Additional information will be available within the Investors &amp; Media section of HOOKIPA\u2019s website at https:\/\/ir.hookipapharma.com\/events. About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body\u2019s immune system. HOOKIPA\u2019s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+\u00a0T cells and pathogen-neutralizing antibodies. HOOKIPA\u2019s viral vectors target &hellip; Continue reading \"HOOKIPA Pharma to Present at Kempen Life Science Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-14T12:03:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjgxOSM0MTIwNTY3IzIxNTY5MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HOOKIPA Pharma to Present at Kempen Life Science Conference","datePublished":"2021-04-14T12:03:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/"},"wordCount":316,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjgxOSM0MTIwNTY3IzIxNTY5MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/","name":"HOOKIPA Pharma to Present at Kempen Life Science Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjgxOSM0MTIwNTY3IzIxNTY5MjI=","datePublished":"2021-04-14T12:03:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjgxOSM0MTIwNTY3IzIxNTY5MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjgxOSM0MTIwNTY3IzIxNTY5MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-present-at-kempen-life-science-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HOOKIPA Pharma to Present at Kempen Life Science Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=476062"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476062\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=476062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=476062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=476062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}